All In Biotech

Drug Trial Radar · NCT06193889

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Aug 28, 2024

Primary completion

Sep 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Kyverna TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Conditions

  • Myasthenia Gravis
  • Generalized Myasthenia Gravis

Interventions

  • Standard of Care TreatmentDrug

    Standard of Care Medications Optional Crossover to receive KYV-101 treatment

  • Standard lymphodepletion regimenDrug

    Standard lymphodepletion regimen

  • KYV-101Biological

    Anti-CD19 CAR-T cell therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)Time frame: 18 months
  2. Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2)Time frame: 24 weeks
  3. Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)Time frame: 24 weeks
  4. Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)Time frame: 24 weeks

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • University of California, Irvine

    Orange, California · Recruiting

  • Stanford University Medical Center

    Palo Alto, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Indiana University Health

    Indianapolis, Indiana · Recruiting

  • University of Missouri

    Columbia, Missouri · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • Westmead Institute for Medical Research

    Westmead, Australia · Recruiting

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil · Recruiting

  • Charite- Universitätsklinikum Berlin

    Berlin, Germany · Recruiting

  • Universitätsklinikum der Ruhr-Universität Bochum

    Bochum, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Medizinische Hochscule Hannover

    Hanover, Germany · Recruiting

  • Friedrich-Schiller-Universität Jena

    Jena, Germany · Recruiting

  • Universitätsklinik Magdeburg

    Magdeburg, Germany · Recruiting

  • Technical University Munich, Klinikum Rechts der Isar

    Munich, Germany · Recruiting

  • King's Faisal Specialist Hospital and Research Center

    Riyadh, Kindom of Saudi Arabia, Saudi Arabia · Recruiting

  • Cambridge University Hospital, Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • King's College Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.